Aurobindo Pharma Gets USFDA Approval for First Metered-Dose Inhaler

The cited US market opportunity was $301 million for the 12 months ended July 2026.

Aurobindo Pharma's cumulative USFDA approvals have reached 596, comprising 571 final and 25 tentative approvals.

Reader Takeaway: Complex respiratory expansion strengthens the US portfolio; commercial contribution now depends on launch execution and market uptake.

What just happened

Aurobindo Pharma Ltd has secured final approval from the US Food and Drug Administration for Beclomethasone Dipropionate HFA Inhalation Aerosol in 40 mcg and 80 mcg strengths.

The product is a generic equivalent of QVAR Inhalation Aerosol from Teva Branded Pharmaceutical Products. It is indicated for maintenance treatment of asthma as prophylactic therapy in patients aged five years and above.

The approval is particularly relevant because this is Aurobindo Pharma's first metered-dose inhaler, or MDI, product. The company expects to launch it in upcoming quarters.

Why this matters

The approval moves Aurobindo Pharma further into complex respiratory products rather than relying only on conventional oral generics in the US market.

The company cited IQVIA data showing that the US market for the approved product and newer versions of the reference product, QVAR RediHaler, was about $301 million for the 12 months ended July 2026. That figure represents the addressable market cited by the company, not Aurobindo Pharma's expected sales from the product.

The commercial opportunity will therefore depend on the launch schedule, competitive conditions and the share Aurobindo can capture after entering the market.

What changes now

The inhaler will be manufactured at the Raleigh, North Carolina facility operated by Aurolife Pharma LLC, Aurobindo Pharma's wholly owned step-down subsidiary.

Having an approved MDI produced from its US facility gives the company a platform for expanding its respiratory portfolio if further products progress through development and regulatory approval.

The latest clearance also lifts Aurobindo Pharma's cumulative USFDA approval count to 596. Of these, 571 are final approvals and 25 are tentative approvals.

Risks to watch

Regulatory approval clears a major hurdle, but it does not guarantee a specific revenue contribution. Investors still need visibility on the actual launch date, competitive intensity, pricing and the pace of commercial adoption.

The $301 million figure also covers the approved product and newer versions of the reference product, so it should not be treated as the revenue pool automatically available to Aurobindo Pharma.

What to track next

The next material milestone is commercial launch in the US. Investors should watch subsequent company disclosures for launch timing and any indication of how quickly the first MDI product begins contributing to the US business.

Further respiratory approvals would also be important because they would show whether this first MDI clearance is developing into a broader complex-product franchise.